A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

NCT06046495 · tracked via the Priya Life Science USA tracker

Sponsor

Avistone Biotechnology Co., Ltd.

Phase

Phase 1

Started

2024-07-08

Last updated

2025-04-23

Condition(s) studied

Non-Small Cell Lung Cancer

Investigational drug(s) / intervention(s)

PLB1004

PLB1004: PLB1004 will be orally self-administered by the patient as a mono-therapy.

Study summary

This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations，uncommon mutations, classical mutations (Ex19del and L858R), and drug-resistant mutation (T790M). Patients will be enrolled and dosed according to the most current protocol. This study is made of two Parts. Part 1 includes a dose escalation into 7 cohorts and patient allocation to these cohorts will be via slot allocation. Each cohort has a minimum of 3 and a maximum of 6 patients for a total of 21 - 42 patients. The patient population of the dose escalation phase will include patients with advanced NSCLC harboring EGFR classical mutations or Ex20ins mutations, or uncommon mutations. Part 2 includes an expansion phase and the expansion phase will explore one or more dose levels of PLB1004 in NSCLC patients with EGFR Ex20ins mutations, classical mutations, or uncommon mutations.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Ability to understand and willingness to sign a written informed consent document; 2. Male or female adult patients 18 years of age or older; 3. Patients should have recovered from toxicities related to prior anti-tumor therapy; 4. Patients should have recovered from the effects of major surgery; 5. Have a documented EGFR mutation by a local test in tissue or plasma; 6. At least 12 weeks life expectancy; 7. Must have at least one measurable lesion per RECIST v 1.1; 8. Sexually active males and females of childbearing potential must agree to take effective contraceptive measures. Exclusion Criteria: 1. Received radiotherapy within 14 days before enrollment; 2. Have significant or uncontrolled systemic disease; 3. Have significant or uncontrolled cardiovascular disease; 4. Have had other diagnosed malignant diseases that required treatment within the past 3 years besides NSCLC; 5. Currently have or had a history of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonia that requires steroid therapy; 6. Have known hypersensitivity to the similar drugs and excipients of PLB1004; 7. Pregnant or lactating women; 8. Have used other experimental drugs within 2 weeks prior to the first dose of PLB1004; 9. Have any condition or illness that could affect the compliance with the protocol.

Primary outcome measure(s)

Safety profile of PLB1004 per CTCAE v5.0 — Up to 2 years

Trial sites (7)

Facility	City	Region	Status
University of California-Davis	Sacramento	California	Recruiting
Research Site	Louisville	Kentucky	Recruiting
Nebraska Cancer Specialists	Omaha	Nebraska	Recruiting
Research Site	New York	New York	Recruiting
Sarah Cannon Research Institute	Nashville	Tennessee	Recruiting
Swedish Health Sciences	Seattle	Washington	Recruiting
Research Site	Seattle	Washington	Recruiting

More Avistone Biotechnology Co., Ltd. trials in the USA

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting

A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer Recruiting

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting

Other trials for the same condition

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer Recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Recruiting

A Study of IBI363 in Subjects with Advanced Solid Malignancies Recruiting

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06046495 on ClinicalTrials.gov ↗ ← All trials in the USA